In Clinical

Follow this topic

Record learning outcomes

The MHRA has published a revised Drug Safety Update for valproate.

It states that while the requirement for a review by two specialists remains in place for patients initiating valproate under 55 years of age, the Commission on Human Medicines has advised that it will not be required for men (or males) currently taking valproate.

The regulator has produced three infographics to clarify in which situations review by two specialists may be required, as well as a list of who might qualify as a specialist.

Resources and information about valproate from the GPhC are available here.